Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (341-350 of 385) with videos related to

Pageof 39
Sort By:
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Journal of the American College of Cardiology|April 19, 2023
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced CancerAlessia Lena, Ursula Wilkenshoff, Sara Hadzibegovic, et al.
Cancer|November 28, 2018
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machineryGiorgia Simonetti, Antonella Padella, Italo Farìa do Valle, et al.
Nature|August 3, 2018
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDH<sup>mut</sup>-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Nature Cancer|June 28, 2024
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunitiesEvelyn Ramberger, Valeriia Sapozhnikova, Yuen Lam Dora Ng, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
The Journal of Clinical Investigation|May 9, 2017
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsMargaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
International Journal of Cancer|July 13, 2022
Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patientsJoanna Zaleska, Paulina Kwasnik, Magdalena Paziewska, et al.
Pageof 39

Showing results (341-350 of 385) with videos related to

Sort By:
Pageof 39
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Journal of the American College of Cardiology|April 19, 2023
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced CancerAlessia Lena, Ursula Wilkenshoff, Sara Hadzibegovic, et al.
Cancer|November 28, 2018
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machineryGiorgia Simonetti, Antonella Padella, Italo Farìa do Valle, et al.
Nature|August 3, 2018
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDH<sup>mut</sup>-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Nature Cancer|June 28, 2024
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunitiesEvelyn Ramberger, Valeriia Sapozhnikova, Yuen Lam Dora Ng, et al.
Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.
The Journal of Clinical Investigation|May 9, 2017
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsMargaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, et al.
Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.
International Journal of Cancer|July 13, 2022
Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patientsJoanna Zaleska, Paulina Kwasnik, Magdalena Paziewska, et al.
Pageof 39